Literature DB >> 6403470

Preparation and physicochemical and immunological characterization of polysaccharide-outer membrane protein complexes of Neisseria meningitidis.

E C Beuvery, F Miedema, R W van Delft, J Haverkamp, A B Leussink, B J te Pas, K S Teppema, R H Tiesjema.   

Abstract

A crude complex containing group C polysaccharide, outer membrane proteins, and lipopolysaccharide (LPS) was isolated from the cell-free culture liquid of Neisseria meningitidis serogroup C, serotype 2a. Group C polysaccharide and LPS were removed from this complex, resulting in an outer membrane complex and a purified complex, respectively. Analysis by electron microscopy showed the outer membrane origin of the crude complex and the outer membrane complex, whereas such a structure was absent in the purified complex. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis patterns of the three complexes were identical. Pyrolysis-mass spectrometry data correlated well with those obtained by the biochemical assays and suggested a low LPS content in the purified complex and a low polysaccharide content in the outer membrane complex. The purified complex was shown to be nonpyrogenic and could be prepared with the same yield as that of purified polysaccharide. The immunogenic activities of the complexes were studied in mice. The antibodies were measured by the enzyme-linked immunosorbent assay; and the bactericidal antibody assay. All complexes induced immunoglobulin G antibodies to group C polysaccharide as well as to the serotype antigen, although the removal of polysaccharide and LPS resulted in a reduction of the immunogenic activities of outer membrane complex and purified complex, respectively. A second dose of all complexes produced a clear booster effect of both antibody responses. The antibodies were bactericidal.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403470      PMCID: PMC264857          DOI: 10.1128/iai.40.1.369-380.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method.

Authors:  L SVENNERHOLM
Journal:  Biochim Biophys Acta       Date:  1957-06

2.  Quantitative and qualitative studies on the primary antibody response to pneumococcal polysaccharides at ehe cellular level.

Authors:  P H Baker; P W Stashak
Journal:  J Immunol       Date:  1969-12       Impact factor: 5.422

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Characterization of Neisseria meningitidis capsular polysaccharides containing sialic acid by pyrolysis mass spectrometry.

Authors:  J Haverkamp; H L Meuzelaar; E C Beuvery; P M Boonekamp; R H Tiesjema
Journal:  Anal Biochem       Date:  1980-05-15       Impact factor: 3.365

5.  Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans.

Authors:  W D Zollinger; R E Mandrell; P Altieri; S Berman; J Lowenthal; M S Artenstein
Journal:  J Infect Dis       Date:  1978-06       Impact factor: 5.226

6.  Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.

Authors:  W D Zollinger; R E Mandrell; J M Griffiss; P Altieri; S Berman
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

7.  Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

Authors:  H Peltola; H Mäkelä; H Käyhty; H Jousimies; E Herva; K Hällström; A Sivonen; O V Renkonen; O Pettay; V Karanko; P Ahvonen; S Sarna
Journal:  N Engl J Med       Date:  1977-09-29       Impact factor: 91.245

8.  Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland.

Authors:  H Peltola; H Käyhty; A Sivonen; H Mäkelä
Journal:  Pediatrics       Date:  1977-11       Impact factor: 7.124

9.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors:  C E Frasch; J D Robbins
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  12 in total

1.  Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific.

Authors:  A Pettersson; B Kuipers; M Pelzer; E Verhagen; R H Tiesjema; J Tommassen; J T Poolman
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

2.  Immunogenic activity of gonococcal protein I in mice with three different lipoidal adjuvants delivered in liposomes and in complexes.

Authors:  W Jiskoot; T Teerlink; M M Van Hoof; K Bartels; V Kanhai; D J Crommelin; E C Beuvery
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

3.  Topology of outer membrane porins in pathogenic Neisseria spp.

Authors:  P van der Ley; J E Heckels; M Virji; P Hoogerhout; J T Poolman
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

4.  Thymic-dependence and immune memory in mice vaccinated with meningococcal polysaccharide group B complexed to outer membrane protein.

Authors:  C Moreno; J Esdaile; M R Lifely
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

5.  Immunogenic properties of Klebsiella pneumoniae type 2 capsular polysaccharide.

Authors:  A Robert; H Jouin; J M Fournier
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

6.  Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination.

Authors:  R E Mandrell; W D Zollinger
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

7.  Comparison of meningococcal outer membrane protein vaccines solubilized with detergent or C polysaccharide.

Authors:  J T Poolman; H A Timmermans; C T Hopman; T Teerlink; P A Van Vught; M H Witvliet; E C Beuvery
Journal:  Antonie Van Leeuwenhoek       Date:  1987       Impact factor: 2.271

8.  Induction of mucosal immunoglobulin A immune response by preparations of Neisseria gonorrhoeae porin proteins.

Authors:  S H Jeurissen; T Sminia; E C Beuvery
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

9.  The nature of an in vivo anti-capsular polysaccharide response is markedly influenced by the composition and/or architecture of the bacterial subcapsular domain.

Authors:  Swadhinya Arjunaraja; Paola Massari; Lee M Wetzler; Andrew Lees; Jesus Colino; Clifford M Snapper
Journal:  J Immunol       Date:  2011-12-07       Impact factor: 5.422

10.  Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model.

Authors:  L Y Wang; C E Frasch
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.